INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Attorney Docket Number	4239-67784-01
Application Number	10/789,400
Filing Date	February 27, 2004
First Named Inventor	Collins
Art Unit	1632
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

NOTE APPLICATION was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55).

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
gu		2002/0155581	10/24/2002	Murphy et al.
1		2003/0232326	12/18/2003	Fouchier et al.
		2004/0005544	01/08/2004	Fouchier et al.
		5,993,824	11/30/1999	Murphy et al.
		6,264,957	07/24/2001	Collins
		6,410,023	06/25/2002	Durbin et al.
		6,689,367	02/10/2004	Collins et al.
Luc		6,713,066	03/30/2004	Collins et al.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
Gr	-	WIPO	WO 97/12032 A1	03.04.1997	The Government of the United States of America
		WIPO	WO 98/02530 A1	22.01.1998	The Government of the United States of America
		WIPO	WO 98/53078 A1	26.11.1998	The Government of the United States of America
		WIPO	WO 00/61611 A3	19.10.2000	The Government of the United States of America
SN		WIPO .	WO 00/61737 A2	19.10.2000	The Government of the United States of America

EXAMINER	C111	10-	DATE	12-2126
SIGNATURE:	7000		CONSIDERED:	12-2/20

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

						· · · · · · · · · · · · · · · · · · ·
				Attorney Docket 1		4239-67784-01
			Application Numb	oer	10/789,400	
INFOR	MATION	DISCLOSU	RE STATEMENT [Filing Date		February 27, 2004
	E	Y APPLICA	NT	First Named Inver	ntor	Collins
				Art Unit		1632
				Examiner Name		Not yet assigned
Lu	T T	WIPO	WO 01/03744 A2	18.01.2001	The G	overnment of the United
40						of America
1	· .	WIPO	WO 01/04320 A1	18.01.2001		overnment of the United
						of America
- 1		WIPO	WO 01/04335 A2	18.01.2001		overnment of the United
			1770 01/10/15 10	14060001		of America
l		WIPO	WO 01/42445 A2	14.06.2001		overnment of the United
		MIDO	WO 02/057302 A2	25.07.2002		of America Clincs B.V.
>~		WIPO	WO 02/03/302 A2	23.07.2002	VIIO-	CHINGS B. V.
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS				
5N		Nucleocapsid N Protein Has Been Replaced by That of Bovine PIV3 Is Attenuated in Primates," J. Virol. 74:3188-3195 (2000). Baron and Barrett, "Rescue of Rinderpest Virus from Cloned cDNA," J. Virol. 71:1265-1271 (1997). Bastien et al., "Sequence Analysis of the N, P, M and F Genes of Canadian Human Metapneumovirus Strains," Virus Res. 93:51-62 (2003). Beeler and van Wyke Coelingh, "Neutralization Epitopes of the F Glycoprotein of Respiratory Syncytial Virus: Effect of Mutation Upon Fusion Function," J. Virol. 63:2941:2950 (1989). Bermingham and Collins, "The M2-2 Protein of Human Respiratory Syncytial Virus is a Regulatory Factor Involved in the Balance Between RNA Replication and Transcription," Proc. Natl. Acad. Sci. USA 96:11259-11264 (1999).				
		Bukreyev et al., "Interferon γ Expressed by a Recombinant Respiratory Syncytial Virus Attenuates Virus Replication in Mice Without Compromising Immunogenicity," <i>Proc. Natl. Acad. Sci. USA 96</i> :2367-2372 (1999). Bukreyev et al., "Recovery of Infectious Respiratory Syncytial Virus Expressing an Additional Foreign Gene." <i>I. Viral.</i> 70:6634 6641 (1996).				
4n		Additional, Foreign Gene," J. Virol. 70:6634-6641 (1996). Collins et al., "Production of Infectious Human Respiratory Syncytial Virus from Cloned cDNA Confirms an Essential Role for the Transcription Elongation Factor from the 5' Proximal Open Reading Frame of the M2 mRNA in Gene Expression and Provides a Capability for Vaccine Development," Proc. Natl. Acad. Sci. USA 92:11563-11567 (1995).				

EXAMINER SIGNATURE:	5 Mben	DATE CONSIDERED: 12-16
SIGNATURE:		CONSIDERED.

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

		Attorney Docket Number	4239-67784-01
•		Application Number	10/789,400
INFORMA	TION DISCLOSURE STATEMENT	Filing Date	February 27, 2004
	BY APPLICANT	First Named Inventor	Collins
		Art Unit	1632
		Examiner Name	Not yet assigned
4rl	Connors et al., "A Cold-Passaged, A Virus Contains Mutations in the F a	nd L Genes," Virology 208:4	78-484 (1995).
	Connors et al., "Respiratory Syncyti	ial Virus (RSV) F, G, M2 (22	K), and N Proteins Each
	Induce Resistance to RSV Challeng		M2 and N Proteins is
	Relatively Short-Lived," J. Virol. 63	5:1634-1637 (1991).	DATA 1 D : 1' 4'
	Dimock and Collins, "Rescue of Sy	nthetic Analogs of Genomic	KNA and Replicative-
	Intermediate RNA of Human Parain Durbin et al., "Human Parainfluenza		
	Protein of Measles Virus Provides a	Potential Method for Immur	nization Against Measles
	Virus and PIV3 in Early Infancy," J		
Durbin et al., "Mutations in the C, D, and V Open Reading Frames of			es of Human
Parainfluenza Virus Type 3 Attenuate Replication in Rodents and Primates," Virol			d Primates," Virology
	<i>261</i> :319-330 (1999).		
	Durbin et al., "Recovery of Infectious Human Parainfluenza Virus Type 3 from cDNA," Virology 235:323-332 (1997).		
	Feller et al., "Comparison of Identic	cal Temperature-Sensitive Mu	utations in the L
	Polymerase Proteins of Sendai and (2000).		
	Firestone et al., "Nucleotide Sequence Analysis of the Respiratory Syncytial Virus Subgroup A Cold-Passaged (cp) Temperature Sensitive (ts) cpts-248-404 Live Attenuated Virus Vaccine Candidate," Virology 225:419-422 (1996).		
	Haller et al., "A Single Amino Acid Substitution in the Viral Polymerase Creates a Temperature-Sensitive and Attenuated Recombinant Bovine Parainfluenza Virus Type 3," Virology 288:342-350 (2001).		
	Hardy and Wertz, "The Cys ₃ -His ₁ Motif of the Respiratory Syncytial Virus M2-1 Protein Is Essential for Protein Function," J. Virol. 74:5880-5885 (2000).		
	Hassett and Condit, "Targeted Construction of Temperature-Sensitive Mutations in		
	Vaccinia Virus by Replacing Clustered Charged Residues with Alanine," Proc. Natl.		
	Acad. Sci. USA 91:4554-4558 (1994)	4).	Symmosian of a Paraign
	He et al., "Recovery of Infectious S Gene," Virology 237:249-260 (1997)		expression of a roteign
Gw.	Hoffman and Banerjee, "An Infecti J. Virol. 71:4272-4277 (1997).	ous Clone of Human Parainfl	uenza Virus Type 3,"

EXAMINER SIGNATURE:	4 Chen	DATE CONSIDERED:	12-210 B
biolivatole.	/ 0 / 0	_ CONGIDERED.	

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

		Attorney Docket Number	4239-67784-01	
		Application Number	10/789,400	
INFORM	ATION DISCLOSURE STATEMENT	Filing Date	February 27, 2004	
	BY APPLICANT	First Named Inventor	Collins	
		Art Unit	1632	
		Examiner Name	Not yet assigned	
41	Jin et al., "Respiratory Syncytial Vin (M2-2) Has Altered Growth Character 74:74-82 (2000).	teristics and Is Attenuated in	Rodents," J. Virol.	
l	Jin et al., "Recombinant Human Res Construction of Subgroup A and B			
	Juhasz et al., "The Major Attenuation			
	Vaccine Candidate cpts530/1009 Sp	-	-	
	and Replication and a Non-Tempera J. Virol. 73:5176-5180 (1999).			
	Juhasz et al., "The Temperature-Sen			
		Attenuated Respiratory Syncytial Virus Vaccine Candidate, Designated cpts530, Results from a Single Amino Acid Substitution in the L Protein," J. Virol. 71:5814-5819 (1997).		
 				
	Kato et al., "The Paramyxovirus, Sendai Virus, V Protein Encodes a Luxury Function Required for Viral Pathogenesis," <i>EMBO J. 16</i> :578-587 (1997).			
	Kretzschmar et al., "Normal Replication of Vesicular Stomatitis Virus Without C			
	Proteins," Virology 216:309-316 (1996).			
	Lambert et al., "Peptides from Conserved Regions of Paramyxovirus Fusion (F) Proteins			
		are Potent Inhibitors of Viral Fusion," Proc. Natl. Acad. Sci. USA 93:2186-2191 (1996).		
\ \ \		Lu et al., "Identification of Temperature-Sensitive Mutations in the Phosphoprotein of		
	Respiratory Syncytial Virus That are Likely involved in Its Interaction with the			
		Nucleoprotein," J. Virol. 76:2871-2880 (2002).		
	Newman et al., "Sequence Analysis of the Washington/1964 Strain of Human Parainfluenza Virus Type 1 (HPIV1) and Recovery and Characterization of Wild-Type			
	Recombinant HPIV1 Produced by Reverse Genetics," <i>Virus Genes. 24</i> :77-92 (2002). Peret et al., "Characterization of Human Metapneumoviruses Isolated from Patients in			
		North America," J. Infect. Dis. 185:1660-1663 (2002).		
	Radecke and Billeter, "The Nonstructural C Protein is Not Essential for Multiplication of			
	Edmonston B Strain Measles Virus			
	Schmidt et al., "Bovine Parainfluenz			
	Neuraminidase Glycoproteins Make	-		
	Replication of BPIV3 in Primates,"			
Su	<u> </u>	Skiadopoulos et al., "Determinants of the Host Range Restriction of Replication of Bovine Parainfluenza Virus Type 3 in Rhesus Monkeys are Polygenic," J. Virol. 77:1141-1148		

	EXAMINER SIGNATURE:	5 Mbn	DATE CONSIDERED:	12-21-06
--	------------------------	-------	---------------------	----------

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

		Attorney Docket Number	4239-67784-01	
li .		Application Number	10/789,400	
INFORMATIO	N DISCLOSURE STATEMENT	Filing Date	February 27, 2004	
	BY APPLICANT	First Named Inventor	Collins	
		Art Unit	1632	
		Examiner Name	Not yet assigned	
Gu		a Parainfluenza Virus Type 1 Vaccine Candidate by ins of the Live-Attenuated PIV3 cp45 Vaccine Virus ecine 18:503-510 (2000).		
	Skiadopoulos et al., "Attenuation of the Recombinant Human Parainfluenza Virus Type 3 cp45 Candidate Vaccine Virus is Augmented by Importation of the Respiratory Syncytial Virus cpts530 L Polymerase Mutation," Virology 260:125-135 (1999).			
	Skiadopoulos et al., "Identification of Mutations Contributing to the Temperature-Sensitive, Cold-Adapted, and Attenuation Phenotypes of the Live-Attenuated Cold-Passage 45 (cp45) Human Parainfluenza Virus 3 Candidate Vaccine," J. Virol. 73:1374-1381 (1999).			
	Skiadopoulos et al., "Three Amino Acid Substitutions in the L Protein of the Human Parainfluenza Virus Type 3 cp45 Live Attenuated Vaccine Candidate Contribute to Its Temperature-Sensitive and Attenuation Phenotypes," J. Virol. 72:1762-1768 (1998).			
	Tang et al., "Clustered Charge-to-Alanine Mutagenesis of Human Respiratory Syncytial Virus L Polymerase Generates Temperature-Sensitive Viruses," Virology 302:207-216 (2002).			
	Tang et al., "Requirement of Cysteines and Length of the Human Respiratory Syncytial Virus M2-1 Protein for Protein Function and Virus Viability," J. Virol. 75:11328-11335 (2001).			
	Tao et al., "Construction of a Live-Attenuated Bivalent Vaccine Virus Against Human Parainfluenza Virus (PIV) Types 1 and 2 Using a Recombinant PIV3 Backbone," <i>Vaccine</i> 19:3620-3631 (2001).			
	Tao et al., "A Live Attenuated Chimeric Recombinant Parainfluenza Virus (PIV) Encoding the Internal Proteins of PIV Type 3 and the Surface Glycoproteins of PIV Type 1 Induces Complete Resistance to PIV1 Challenge and Partial Resistance to PIV3 Challenge," Vaccine 17:1100-1108 (1999).			
	Tao et al., "Recovery of a Fully Viable Chimeric Human Parainfluenza Virus (PIV) Type 3 in Which the Hemagglutinin-Neuraminidase and Fusion Glycoproteins Have Been Replaced by Those of PIV Type 1," J. Virol. 72:2955-2961 (1998).			
	Teng et al., "Contribution of the Respiratory Syncytial Virus G Glycoprotein and its Secreted and Membrane-Bound Forms to Virus Replication In Vitro and In Vivo," Virology 289:283-296 (2001).			
LN	van den Hoogen et al., "Analysis of the Genomic Sequence of a Human Metapneumovirus," Virology 295:119-132 (2002).			

EXAMINER SIGNATURE:	4Men	DATE CONSIDERED: 12-21-06

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

4239-67784-01 Attorney Docket Number **Application Number** 10/789,400 February 27, 2004 Filing Date INFORMATION DISCLOSURE STATEMENT First Named Inventor Collins BY APPLICANT Art Unit 1632 Not yet assigned **Examiner Name** van den Hoogen et al., "A Newly Discovered Human Pneumovirus Isolated from Young Children With Respiratory Tract Disease," Nature Med. 7:719-724 (2001). van Wyke Coelingh and Tierney, "Antigenic and Functional Organization of Human Parainfluenza Virus Type 3 Fusion Glycoprotein," J. Virol. 63:375-382 (1989). Wertman et al., "Systematic Mutational Analysis of the Yeast ACT1 Gene," Genetics 132:337-350 (1992). Whitehead et al., "Recombinant Respiratory Syncytial Virus Bearing a Deletion of Either the NS2 or SH Gene is Attenuated in Chimpanzees," J. Virol. 73:3438-3442 (1999). Whitehead et al., "Addition of a Missense Mutation Present in the L Gene of Respiratory Syncytial Virus (RSV) cpts530/1030 to RSV Vaccine Candidate cpts248/404 Increases Its Attenuation and Temperature Sensitivity," J. Virol. 73:871-877 (1999). Whitehead et al., "A Single Nucleotide Substitution in the Transcription Start Signal of the M2 Gene of Respiratory Syncytial Virus Vaccine Candidate cpts248/404 is the Major Determinant of the Temperature-Sensitive and Attenuation Phenotypes," Virology 247:232-239 (1998). Whitehead et al., "Recombinant Respiratory Syncytial Virus (RSV) Bearing a Set of 5W Mutations from Cold-Passaged RSV is Attenuated in Chimpanzees," J. Virol. 72:4467-4471 (1998).

EXAMINER SIGNATURE:	5 Mun	DATE CONSIDERED:	12-2/06	
SIGNATURE:		CONSIDERED:		

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.